ABT
60
-2
CAT
65
15
DAL
42
2
BF.B
55
4
RCL
58
-11
QRVO
40
-2
NEE
47
-3
DHR
57
-9
AMAT
49
-3
FFIV
58
3
WM
65
-12
CMCSA
41
2
SPG
48
-2
SWK
80
7
SLB
60
12
SCHW
45
3
VNO
50
3
GWW
50
2
STT
60
4
PLD
64
-2
ABT
60
-2
CAT
65
15
DAL
42
2
BF.B
55
4
RCL
58
-11
QRVO
40
-2
NEE
47
-3
DHR
57
-9
AMAT
49
-3
FFIV
58
3
WM
65
-12
CMCSA
41
2
SPG
48
-2
SWK
80
7
SLB
60
12
SCHW
45
3
VNO
50
3
GWW
50
2
STT
60
4
PLD
64
-2
Financhill
Back

Beam Therapeutics 10K Form

Buy
71

BEAM
Beam Therapeutics

Last Price:
33.16
Seasonality Move:
-10%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

2023-11-08 10Q BEAM/Beam Therapeutics Quarterly
2023-08-08 10Q BEAM/Beam Therapeutics Quarterly
2023-05-10 10Q BEAM/Beam Therapeutics Quarterly
2022-11-07 10Q BEAM/Beam Therapeutics Quarterly
2022-08-09 10Q BEAM/Beam Therapeutics Quarterly
2022-05-09 10Q BEAM/Beam Therapeutics Quarterly

Receive BEAM News And Ratings

See the #1 stock for the next 7 days that we like better than BEAM

BEAM Financial Statistics

Sales & Book Value

Annual Sales: $377.71M
Cash Flow: $-102.19M
Price / Cash Flow: 0
Annual Sales: $11.10
Price / Book: 2.9

Profitability

EPS (TTM): -1.78000
Net Income (TTM): $-134.74M
Gross Margin: $1.48B
Return on Equity: -15.86%
Return on Assets: -9.91%

Beam Therapeutics Earnings Forecast

Key Beam Therapeutics Financial Ratios

  • The Gross Profit Margin over the past 10 years for BEAM is 58.08%.
  • The Selling, General & Administrative Expenses for BEAM have been equal to 30.93% of Gross Profit Margin.
  • The Research & Development expenses have been 115.80% of Revenue.
  • The Interest Expense is -0.24% of Operating Income.
  • The Net Earning history of BEAM is -35.09% of Total Revenues.
  • Per Share Earnings over the last 16 years have been positive in 6 years.

Beam Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: BEAM
CUSIP: 07373V
Website: beamtx.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 5.99
Quick Ratio: 5.85

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

BEAM Technical Analysis vs Fundamental Analysis

Buy
71
Beam Therapeutics (BEAM) is a Buy

Is Beam Therapeutics a Buy or a Sell?

  • Beam Therapeutics stock is rated a Buy
    The current Beam Therapeutics [BEAM] share price is $32.14. The Score for BEAM is 71, which is 42% above its historic median score of 50, and infers lower risk than normal.